Researchers at ESTRO 2026 reported targeted stereotactic body radiotherapy (SBRT) data for oligometastatic breast cancer, indicating potential for extending control and progression-free survival in patients whose disease has begun to spread. The presentation focused on how targeted radiotherapy regimens may help maintain longer periods of disease control in a setting where conventional systemic strategies can leave patients needing better local disease management. The study’s framing centers on extending progression-free survival, with the approach designed to limit disease spread while targeting specific metastatic sites. For biotech stakeholders, the read-through is increased interest in precision radiotherapy combinations and patient selection strategies, particularly where biomarker-defined or image-guided targeting can strengthen trial endpoints.